Table I.
CGVHD patient demographics
| Patient | Microarray N = 26 | Nanostring N = 69* | ||
|---|---|---|---|---|
| Median (Range) | Number of Patients | Median (Range) | Number of Patients | |
| Age | 42 (21–63) | 46 (21–68) | ||
| Sex (Male/Female) | 17/9 | 38/31 | ||
| HSCT Myeloablative/Nonmyeloablative | 16/10 | 39/30 | ||
| Donor: Related/ Unrelated/Haplo | 14/12/0 | 43/26/0 | ||
| Donor Source: BM/PBSC/CB | 3/23/0 | 13/55/1 | ||
| TBI | 13/13 | 27/42 | ||
| Months from Transplant to Evaluation | 29 (6–74) | 38 (5–258) | ||
| Months from CGVHD Diagnosis | 20 (2–67) | 27 (0–240) | ||
| Onset: (Progressive/Quiescent/De novo) | 7/10/9 | 26/20/24 | ||
| Lines of Prior Systemic Therapy | 4 (2–8) | 4 (0–9) | ||
| Current Systemic Therapy | ||||
| Prednisone | 17 | 46 | ||
| Tacrolimus | 15 | 24 | ||
| MMF | 8 | 20 | ||
| Sirolimus | 4 | 14 | ||
| ECP | 4 | 14 | ||
| Imatinib | 4 | 5 | ||
| Cyclosporine | 1 | 6 | ||
| None | 2 | 9 | ||
| Other† | 1 | 4 | ||
| Number of Organs Involved | 5 (2–7) | 5 (2–8) | ||
| CGVHD Organ Involvement (0/1/2/3) | ||||
| Vulvo/Vaginal (female only) | 1/4/2/2 | 13/10/4/4 | ||
| Oral | 9/13/3/1 | 20/37/9/3 | ||
| Eye | 2/11/9/3 | 12/26/26/5 | ||
| Liver | 12/11/3/0 | 35/23/10/1 | ||
| GI | 16/6/3/1 | 44/18/5/2 | ||
| Lung | 6/14/3/3 | 17/28/17/7 | ||
| Joints/Fascia | 6/5/13/2 | 18/16/28/7 | ||
| Skin | 0/2/6/18 | 9/6/15/39 | ||
| %Body Surface Area‡ (0, <25%, <50%, >50%) | ||||
| Erythematous | 2/19/4/1 | 21/38/8/2 | ||
| Dermal Sclerotic | 8/14/2/2 | 25/32/9/3 | ||
| Deep Sclerotic | 7/7/8/4 | 27/17/15/10 | ||
| Severity§ (Mild/Moderate/Severe) | 0/7/19 | 0/19/50 | ||
*
All 26 CGVHD patients assessed by microarray, as well as 43 additional CGVHD patients, were analyzed in the Nanostring cohort
†
Other systemic therapies: hydroxychloroquine, montelukast, methotrexate, rituximab
‡
Some patients had combinations of erythematous, dermal and deep sclerotic areas of their skin and were included in more than one category
§
CGVHD Severity as assessed at time of NIH protocol enrollment